Clinical Trial

An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2025 (before its estimated May 18, 2025 completion). Its status may not reflect the trial's current state.
Summary
This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.
Trial Details
NCT Number NCT06953518
Lead Sponsor Qualia Life Sciences
Conditions Inflammation
Enrollment 40 participants
Start Date 2025-05-12
Primary Completion 2025-05-18 (estimated)
Study Completion 2025-05-18 (estimated)
Updated on ClinicalTrials.gov 2025-05-01